| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11. | Innovotech Inc: Innovotech closes $200K convertible debenture financing | 3 | Stockwatch | ||
| 05.11. | Innovotech reports Q3 results | 1 | Seeking Alpha | ||
| 05.11. | Innovotech Inc. Reports Record Revenue For Its Third Quarter. | 1 | TheNewswire | ||
| 16.10. | Innovotech offers $200,000 unsecured convertible debentures | 1 | Seeking Alpha | ||
| 16.10. | Innovotech Inc.: Innovotech makes strategic investments to expand analytical laboratory services and offers an unsecured convertible debenture for $200,000. | 1 | TheNewswire | ||
| 07.10. | Innovotech Inc.: Innovotech Expands Fractional CFO Agreement and Occupies New Office and Lab Space | 2 | TheNewswire | ||
| 20.08. | Innovotech reports Q2 results | 1 | Seeking Alpha | ||
| 20.08. | Innovotech Inc. Reports Results For Its Second Quarter And Half-Year Ended 30 June 2025 | 1 | TheNewswire | ||
| INNOVOTECH Aktie jetzt für 0€ handeln | |||||
| 10.07. | Innovotech Inc: Innovotech grants 33-cent options to directors | 2 | Stockwatch | ||
| 10.07. | Innovotech Inc. Grants Director's Options Subsequent to the Annual Meeting | 3 | TheNewswire | ||
| 09.07. | Innovotech Inc: Innovotech shareholders approve all matters at AGM | 3 | Stockwatch | ||
| 09.07. | Innovotech Inc: Innovotech receives $402,926 (U.S.) for position exit | 1 | Stockwatch | ||
| 09.07. | Innovotech Inc. Announces Annual General and Special Meeting Results, New Director and Corporate Changes | 1 | TheNewswire | ||
| 09.07. | Innovotech Inc. Receives US$402,926 Following Exit from its Position in a Canadian Private Company | 1 | TheNewswire |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| HARMONY BIOSCIENCES | 35,290 | -0,76 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results | ||
| ARCUTIS BIOTHERAPEUTICS | 30,650 | -1,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,630 | +4,99 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| COGENT BIOSCIENCES | 40,250 | -0,35 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| DAY ONE BIOPHARMACEUTICALS | 9,490 | +0,85 % | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 43,110 | -0,58 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 17,900 | +0,45 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 84,12 | +0,55 % | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen |